Korean J Intern Med.
2022 Mar;37(2):271-280. 10.3904/kjim.2021.527.
Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria
- Affiliations
-
- 1Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 3Catholic Hematology Hospital, The Catholic University of Korea, Seoul, Korea
- KMID: 2527290
- DOI: http://doi.org/10.3904/kjim.2021.527
Abstract
- Multidrug resistance in bacteria is an important issue and is increasing in frequency worldwide because of the limitations of therapeutic agents. From 2010 to 2019, 14 new systemic antibiotics received regulatory approval in the United States. However, few new antibiotics have been introduced in Republic of Korea to combat multidrug-resistant pathogens. Here, we introduce six novel antibiotics for Gram-positive bacteria and five for Gram-negative bacteria approved by the United States Food and Drug Administration and the European Medicines Agency from 2009 to October 2021, and recommend that they be approved for use in Republic of Korea at the earliest possible date.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Multidrug-resistant bacteria: a national challenge requiring urgent addressal
- Antibiotics for multidrug-resistant gram-positive bacteria
- Multidrug-Resistant Gram-Positive Bacterial Infections
- Anti-inflammatory and Anti-bacterial Effects of Aloe vera MAP against Multidrug-resistant Bacteria
- Active Surveillance of Multidrug-Resistant Organisms with Rapid Detection Methods for Infection Control
